Beyond the Purpose: Martin Stenfeldt on why traction determines what scales

Beyond the Purpose, a new podcast from BioX, launches with a conversation on the decisions and leadership stories behind scaling life sciences companies. In this first episode, hosts James Cox and Jay Webster sit down with Martin Stenfeldt, CEO at UNEEG Medical, who brings deep experience working with scale-up organisations across life sciences.

The conversation centres on leadership at the moments that matter most: Martin's eight leadership archetypes, why commercialisation is so often approached the wrong way, and what he calls the funding trap, no traction, no future. Martin's new book, Scaling Life Sciences, expands on many of the themes covered in this episode and is available now at scalinglifesciences.com.

It's a thoughtful, challenging conversation that sets the tone for what this podcast is about, understanding what drives exceptional people to build, lead and scale life sciences companies, and what others can learn from them.

What this episode covers

Martin's central argument is that results, not ideas, secure the next round of funding. Without consistent traction, companies struggle to attract new investors, existing investors lose patience, and a stalled raise forces cuts to people or projects, extending time to market and compounding the problem for the round after that. Commercialisation is where the pressure is greatest: some investors, he notes, would rather exit before that stage than absorb the longer timelines and cost it demands.

He sets out eight leadership archetypes observed across life sciences founders, arguing that the risk lies not in any single type but in a leadership team drawn too heavily from just one, a founding team weighted entirely towards scientific backgrounds, for instance, carries blind spots that only become addressable once they can be named. He extends the same thinking to board composition: rather than something founders passively inherit, each funding round is the natural point to have an open conversation about what capability the board needs next.

On culture, Martin describes a two-way relationship with funding. A team anchored to a clear mission and a small number of genuinely lived core values holds its direction and momentum before capital arrives, and knows how to deploy it once it does. A team without that anchor risks pursuing every opportunity new funding opens up, at the expense of the focus that got them there. His guidance for founders raising capital is specific: keep core values to a memorable few, reinforce them consistently across the business, and give investors direct access to the team rather than a description of culture in a deck.

He closes by looking ahead: leadership needs to treat scaling itself as a discipline rather than a phase, build genuine adaptability as AI and geopolitical shifts reshape the sector, and hold a global outlook earlier than most companies do.

Listen and subscribe

Listen to episode one on Spotify or Apple Podcasts or visit the BioX podcast page to stay tuned for future episodes.

To learn more about how BioX helps organisations secure the leaders who drive performance across the full drug development life cycle, visit BioX.